The combination of selpercatinib and crizotinib has achieved successful outcomes in overcoming drug resistance in the treatment of non-small cell lung cancer, providing an important reference for combination therapy in thyroid cancer patients with RET mutations (28). Here, RET is linked to non-small cell lung carcinoma.